Real-World Signals from Treated Children

Article Date
May 19, 2026

This article is featured on another website.

Go to article

Related posts

Browse all articles
March 6, 2026

Labiotech Beyond Biotech podcast with Sean A. MacDonald, CEO of Kainova Therapeutics – Reversing tumor immunosuppression with next-gen GPCR modulation

March 6, 2026

Labiotech Beyond Biotech podcast with Sean A. MacDonald, CEO of Kainova Therapeutics – Reversing tumor immunosuppression with next-gen GPCR modulation

March 10, 2026

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

March 10, 2026

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors